192 related articles for article (PubMed ID: 23726028)
1. Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
Hwang SH; Wecksler AT; Zhang G; Morisseau C; Nguyen LV; Fu SH; Hammock BD
Bioorg Med Chem Lett; 2013 Jul; 23(13):3732-7. PubMed ID: 23726028
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG¹²D/Pdx-1-Cre Mice.
Liao J; Hwang SH; Li H; Liu JY; Hammock BD; Yang GY
Anticancer Res; 2016 Jan; 36(1):27-37. PubMed ID: 26722025
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.
Liu JY; Park SH; Morisseau C; Hwang SH; Hammock BD; Weiss RH
Mol Cancer Ther; 2009 Aug; 8(8):2193-203. PubMed ID: 19671760
[TBL] [Abstract][Full Text] [Related]
5. Biological evaluation of a novel sorafenib analogue, t-CUPM.
Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
[TBL] [Abstract][Full Text] [Related]
6. Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
Kodani SD; Bhakta S; Hwang SH; Pakhomova S; Newcomer ME; Morisseau C; Hammock BD
Bioorg Med Chem Lett; 2018 Feb; 28(4):762-768. PubMed ID: 29366648
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase.
Taylor SJ; Soleymanzadeh F; Eldrup AB; Farrow NA; Muegge I; Kukulka A; Kabcenell AK; De Lombaert S
Bioorg Med Chem Lett; 2009 Oct; 19(20):5864-8. PubMed ID: 19758802
[TBL] [Abstract][Full Text] [Related]
9. Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
Codony S; Valverde E; Leiva R; Brea J; Isabel Loza M; Morisseau C; Hammock BD; Vázquez S
Bioorg Med Chem; 2019 Oct; 27(20):115078. PubMed ID: 31488357
[TBL] [Abstract][Full Text] [Related]
10. Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain.
Lee KSS; Ng JC; Yang J; Hwang SH; Morisseau C; Wagner K; Hammock BD
Bioorg Med Chem; 2020 Nov; 28(22):115735. PubMed ID: 33007552
[TBL] [Abstract][Full Text] [Related]
11. [Advances in the study of structural modifications of multi-target anticancer drug sorafenib].
Yao JW; Sun W; Chen J; Xu WF
Yao Xue Xue Bao; 2012 Sep; 47(9):1111-9. PubMed ID: 23227538
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological activities of sorafenib derivatives as antitumor agents.
Yao J; He Z; Chen J; Sun W; Fang H; Xu W
Bioorg Med Chem Lett; 2012 Nov; 22(21):6549-53. PubMed ID: 23021967
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides.
Morisseau C; Pakhomova S; Hwang SH; Newcomer ME; Hammock BD
Bioorg Med Chem Lett; 2013 Jul; 23(13):3818-21. PubMed ID: 23684894
[TBL] [Abstract][Full Text] [Related]
14. [Synthesis and in vitro cytotoxic activities of sorafenib derivatives].
Wang K; Li Y; Zhang LJ; Yang HZ; Chen XG; Feng ZQ
Yao Xue Xue Bao; 2014 May; 49(5):639-43. PubMed ID: 25151734
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of soluble epoxide hydrolase minimize ischemia-reperfusion-induced cardiac damage in normal, hypertensive, and diabetic rats.
Islam O; Patil P; Goswami SK; Razdan R; Inamdar MN; Rizwan M; Mathew J; Inceoglu B; Stephen Lee KS; Hwang SH; Hammock BD
Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28296232
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and in vitro antitumor activities of novel benzyl urea analogues of sorafenib.
Lu CS; Tang K; Li Y; Jin B; Yin DL; Ma C; Chen XG; Huang HH
Yao Xue Xue Bao; 2013 May; 48(5):709-17. PubMed ID: 23888694
[TBL] [Abstract][Full Text] [Related]
17. Discovery of phthalimide derivatives as novel inhibitors of a soluble epoxide hydrolase.
Mahlooji I; Shokri M; Manoochehri R; Mahboubi-Rabbani M; Rezaee E; Tabatabai SA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000052. PubMed ID: 32484272
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and activity of novel sorafenib analogues bearing chalcone unit.
Wang M; Xu S; Wu C; Liu X; Tao H; Huang Y; Liu Y; Zheng P; Zhu W
Bioorg Med Chem Lett; 2016 Nov; 26(22):5450-5454. PubMed ID: 27777009
[TBL] [Abstract][Full Text] [Related]
19. [Synthesis and biological evaluation of sorafenib thiourea derivatives].
Yang Z; Fang Z; Wang ZX; Wei P
Yao Xue Xue Bao; 2011 Sep; 46(9):1093-7. PubMed ID: 22121780
[TBL] [Abstract][Full Text] [Related]
20. [Design, synthesis and antitumor activity of sorafenib analogues containing 2-picolinylhydrazide moiety].
Qin AF; Li Y; Song HR; Chen XG; Jin XF; Wang K; Zhang LJ; Huo LC; Feng ZQ
Yao Xue Xue Bao; 2012 Dec; 47(12):1623-9. PubMed ID: 23460968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
